Unique basophil microRNA signature in chronic spontaneous urticaria patients who respond to omalizumab

Clin Exp Allergy. 2021 Dec;51(12):1648-1652. doi: 10.1111/cea.14014. Epub 2021 Sep 20.

Authors

Taha Al-Shaikhly¹, James W MacDonald², Theo K Bammler², Matthew C Altman¹, Andrew G Ayars¹, Daniel H Petroni³, Stephen A Tilles³, William R Henderson Jr¹

Affiliations

¹ Division of Allergy and Infectious Diseases, Department of Medicine, School of Medicine, University of Washington, Seattle, WA, USA.
² Interdisciplinary Center for Exposures, Diseases, Genomics & Environment, Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, WA, USA.
³ Seattle Allergy and Asthma Research Institute, Seattle, WA, USA.

PMID: 34519110
DOI: 10.1111/cea.14014

No abstract available

Keywords: Basophils; chronic spontaneous urticarial; microRNA; omalizumab; response biomarker.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Allergic Agents* / therapeutic use
Basophils
Chronic Disease
Chronic Urticaria* / drug therapy
Humans
MicroRNAs*
Omalizumab / therapeutic use
Urticaria* / drug therapy

Substances

Anti-Allergic Agents
MicroRNAs
Omalizumab

Grants and funding

CIGE025EUS44T/Novartis Pharmaceuticals Corporation